Bradenton Research Center | Bradenton, FL
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary Objective:
To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe systemic disease activity.
Secondary Objectives:
Full description
Acquired from Horizon in 2024.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
510 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Amgen Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal